Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial

Mary Gleeson, Eliza A. Hawkes, David Cunningham, Nick Chadwick, Nicholas Counsell, Anthony Lawrie, Andrew Jack, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M. Ardeshna, John Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter W.M. Johnson, Joanna Gambell, David Linch

Research output: Contribution to journalArticleResearchpeer-review

36 Citations (Scopus)


We performed a subgroup analysis of the phase III UK National Cancer Research Institute R-CHOP-14 versus R-CHOP-21 (two- versus three-weekly rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone) trial to evaluate the outcomes for 50 patients with World Health Organization 2008 classified primary mediastinal B-cell lymphoma identified from the trial database. At a median follow-up of 7·2 years the 5-year progression-free survival and overall survival was 79·8% and 83·8%, respectively. An exploratory analysis raised the possibility of a better outcome in those who received R-CHOP-14 and time intensification may still, in the rituximab era, merit testing in a randomised trial in this subgroup of patients.

Original languageEnglish
Pages (from-to)668-672
Number of pages5
JournalBritish Journal of Haematology
Issue number4
Publication statusPublished - Nov 2016
Externally publishedYes


  • clinical trials
  • diffuse large B-cell lymphoma
  • non-Hodgkin lymphoma
  • primary mediastinal B-cell lymphoma
  • rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone

Cite this